Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Endoxifen (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Atossa Genetics
- 11 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to an Atossa Genetics media release.
- 01 Aug 2018 According to an Atossa Genetics media release, Study is now open for enrollment in Sweden.
- 26 Jun 2018 According to an Atossa Genetics media release, enrollment in this trial is anticipated to be completed by the end of 2018.